| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO | Director
2 companies
Stephen Davis last filed a Form 4 in August 2024, as CEO at ACAD. The filings on record cover 2 companies. From October 2019 to August 2024, the filings on record show 0 open-market purchases and 27 sales. Stephen Davis's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Stephen Davis's trades have earned a middling insider score of 68/100 across 21 rated trades. Over a 12-month horizon, 76.2% of those trades were profitable, with an average 12-month return of +7.7%.
At the last filing, the largest reported position was 186,555 shares of ACAD. The ACAD filings lean toward selling, a net 901,217 shares.
Shares as reported in the last Form 4 for each company; the most recent is from August 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 6, 2021 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 3,484 | $53.34 | $185,836.56 | -12.5% | |
| Oct 16, 2020 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 2,960 | $42.56 | $125,977.60 | -16.7% | |
| May 14, 2020 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 200,000 | $46.02 | $9,204,691.76 | -94.4% | |
| Apr 30, 2020 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 6,770 | $49.21 | $333,151.70 | -36.4% | |
| Dec 5, 2019 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 150,000 | $52.34 | $7,851,299.93 | -98.1% | |
| Oct 15, 2019 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 2,983 | $39.65 | $118,275.95 | -50.2% | |
| Oct 10, 2019 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 150,000 | $40.15 | $6,022,749.10 | - |